Work with thought leaders and academic experts from Kyoto University

At present, I combine the practice of architecture with academic activities focused mainly on sustainability. Since 2020, my experience with environmental practices led me to engage with consultancy projects, where I had the chance to help small and medium size companies developing a strong and personalized approach to sustainability. In most cases, people contacted my looking for clarification of the overflow of conflicting information on sustainability measures, regulations, and even ethical stands. My tasks as a consultant included careful interviews with managers and workers, deep research on sustainable standards of several products and services, and the creation of reports, guidelines, and workshops on sustainability issues (in my experience, the most popular subject was “How to avoid unintentional Green-washing”). Looking forward, I intend to strengthen my activities as a sustainability researcher and consultant. Sustainability practices are in constant development and companies need research-based information to keep updated in this regard.

Dr. Shin Mukai, PhD is a highly accomplished chemical biologist with over 20 years of experience in the field. He received his Bachelor's degree in Chemistry from Kyoto University, followed by a Master's degree and PhD in Bio-Organic Chemistry from Kyoto University and the University of Western Australia, respectively. After completing his education, Dr. Mukai worked as a Postdoctoral Research Fellow at Keio University School of Medicine and Brigham and Women's Hospital / Harvard Medical School. During this time, he conducted groundbreaking research in the areas of drug discovery and development, focusing on novel treatments for various diseases. In 2022, Dr. Mukai joined Sanofi as a Scientist III, where he continued his research in drug discovery and development. He opened a new avenue for biology in human B-cells, eosinophills, neutrophils and mast cells, making significant contributions to the field. In 2023, Dr. Mukai co-founded New Wind Therapeutics L3C, a pharmaceutical company that focuses on discovering and developing new small-molecule drugs for the treatment of pancreatic cancer. As the Chief Executive Officer and Chief Scientific Officer, he oversees the company's research and development efforts, utilizing his extensive knowledge and expertise in organic/medicinal chemistry, biology and immunology. Dr. Mukai has published numerous research papers in top scientific journals and has received several awards and honors for his work. He is highly respected in the scientific community and continues to make significant contributions to the field of chemical biology.